ALG-055009 vs VK2809
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
MASH / NASH
Shared mechanism: Thyroid hormone receptor-beta · full MASH / NASH pipeline
ALG-055009
Developed by Aligos Therapeutics
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
VK2809
Developed by Viking Therapeutics and partners
NCT04173065 · Phase 2 · completed
This randomized, quadruple-blind, placebo-controlled Phase 2b trial (n=248) in biopsy-confirmed NASH met its primary endpoint, an imaging marker of liver fat (MRI-PDFF) at 12 weeks, with reductions up to 51.7% versus placebo (p<0.0001). At 52 weeks the sponsor reports biopsy secondary endpoints: NASH resolution in 63% to 75% of VK2809 patients versus 29% on placebo, and fibrosis improvement in 44% to 57% versus 34% (significant in two of the dose arms only). The histology is a secondary endpoint reported by the sponsor; a registrational trial on a histology primary endpoint is still needed.
Caveat: the 12-week and 52-week figures are from company announcements, not from the trial registry or a peer-reviewed full paper. Treat them as the sponsor's own statement.
Reported efficacy
Liver Fat (12 weeks): Primary: liver fat reduction (MRI-PDFF) at Week 12, mean relative change -45.3% (2.5 mg QD), -36.8% (5 mg QOD), -51.7% (10 mg QOD), each p<0.0001 vs placebo. Secondary, 52-week biopsy: NASH resolution with no worsening of fibrosis 63% to 75% vs 29% placebo (p<0.05 each arm); >=1-stage fibrosis improvement with no worsening of NASH 44% to 57% vs 34% placebo (p<0.05 for the 5 mg and 10 mg QOD arms only). (met)
Result source: NCT04173065
Results for MASH / NASH
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ALG-055009 | VK2809 |
|---|---|---|
| MASH resolution without fibrosis worsening | —Not reported | —Not reported |
| Fibrosis stage, change | —Not reported | —Not reported |
| Liver fat (MRI-PDFF), change | —Not reported | —Not reported |
| ALT, change | —Not reported | —Not reported |
MASH resolution without fibrosis worsening
- ALG-055009
- —Not reported
- VK2809
- —Not reported
Fibrosis stage, change
- ALG-055009
- —Not reported
- VK2809
- —Not reported
Liver fat (MRI-PDFF), change
- ALG-055009
- —Not reported
- VK2809
- —Not reported
ALT, change
- ALG-055009
- —Not reported
- VK2809
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
ALG-055009: no structured comparison results are available for MASH / NASH.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
VK2809
show 2 more results
show 2 more results
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ALG-055009's landscape · VK2809's landscape